17:16 EDT AIM ImmunoTech (AIM) files $100M mixed securities shelf
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIM:
- AIM ImmunoTech made ‘significant strides’ over course of 2024
- AIM announces principal investigator for Ampligen, FluMist clinical study
- AIM ImmunoTech Appoints David Chemerow to Board
- AIM ImmunoTech appoints Chemerow as an Independent Director
- AIM ImmunoTech doses first subject in Phase 2 study of Ampligen, Imfinzi